Federal Register / Vol. 86, No. 135 / Monday, July 19, 2021 / Notices 38097 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

National Syringe Services Program 

Evaluation—New—National Center for 

HIV/AIDS, Viral Hepatitis, STD, and TB 

Prevention (NCHHSTP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

The primary purpose of the National 

Syringe Services Program (SSP) 

Evaluation is to strengthen and improve 

the capacity of SSPs to conduct regular 

monitoring and evaluation to ensure 

that comprehensive prevention services 

are provided to meet the needs of 

people who inject drugs (PWID). The 

project will include SSPs that are listed 

in a publicly available directory of all 

known SSPs in the United States 

maintained by the North American 

Syringe Exchange Network (NASEN; 

https://nasen.org). SSPs will be sent a 

letter of invitation to participate in a 35- 

minute program survey, called the Dave 

Purchase Memorial Survey. 

Participating programs will have the 

option of completing the survey via 

different modalities to enhance 

feasibility and comfort in completing 

the survey, for example via the Research 

Electronic Data Capture (REDCap) or a 

similarly secure web-based application. 

Other modalities for survey 

administration will include a 

coordinated telephone or 

videoconferencing interview. 

The survey will include questions on 

operational characteristics and services, 

client characteristics and drug use 

patterns, client satisfaction, funding 

resources, community relations, and key 

operational successes and challenges. 

Approximately 600 SSPs will be able to 

participate in the survey. We anticipate 

that approximately 20% of SSPs will 

decline to complete the survey, yielding 

approximately 480 completed surveys 

per year. However, given that this is the 

first survey of SSPs funded by CDC 

during the COVID–19 pandemic, it 

makes it challenging to predict response 

rates. We estimate that it will take 35 

minutes to complete the survey, 

regardless of how the respondent 

chooses to complete it (i.e., selfadministered online or intervieweradministered by phone or 

videoconferencing). SSPs that do not 

respond to the initial survey invitation 

will be given reminders to complete the 

survey over the duration of the survey 

implementation period. The final 

reminder will include a link to a single 

question for SSPs that choose not to 

complete the survey about why they 

declined to complete the survey. Given 

the uncertainties in response rates 

described above, we are requesting 

enough burden hours to allow at least 

80% of SSPs to respond to this question. 

We estimate that it will take two 

minutes to respond to this question. 

The total estimated annual burden 

hours are 296. There are no other costs 

to respondents other than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses 

per 

respondent 

Average 

burden per 

response 

(hours) 

All participating SSPs ..................................... Survey Y1 and Survey Y2–3 ......................... 480 1 35/60 

Non-responding SSPs .................................... Non-Response Survey Item ........................... 480 1 2/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2021–15226 Filed 7–16–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2021–0070] 

Advisory Committee on Immunization 

Practices (ACIP) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting and request 

for comment. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC), announces the 

following meeting of the Advisory 

Committee on Immunization Practices 

(ACIP). This meeting is open to the 

public. The meeting will be webcast live 

via the World Wide Web. Time will be 

available for public comment. A notice 

of this ACIP meeting has also been 

posted on CDC’s ACIP website at: http:// 

www.cdc.gov/vaccines/acip/index.html. 

In addition, CDC has sent notice of this 

ACIP meeting by email to those who 

subscribe to receive email updates about 

ACIP. 

DATES: The meeting will be held on July 

22, 2021, from 11:00 a.m. to 4:00 p.m., 

EDT (dates and times subject to change), 

see the ACIP website for updates: http:// 

www.cdc.gov/vaccines/acip/index.html. 

The public may submit written 

comments from July 19, 2021 through 

July 22, 2021. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2021– 

0070 by any of the following methods: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

MS H24–8, Atlanta, Georgia 30329– 

4027, Attn: July 22, 2021 ACIP Meeting. 

Instructions: All submissions received 

must include the Agency name and 

Docket Number. All relevant comments 

received in conformance with the 

https://www.regulations.gov suitability 

policy will be posted without change to 

https://www.regulations.gov, including 

any personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

https://www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Stephanie Thomas, ACIP Committee 

Management Specialist, Centers for 

Disease Control and Prevention, 

National Center for Immunization and 

Respiratory Diseases, 1600 Clifton Road 

NE, MS–H24–8, Atlanta, Georgia 30329– 

4027; Telephone: (404) 639–8367; 

Email: ACIP@cdc.gov. 

SUPPLEMENTARY INFORMATION: In 

accordance with 41 CFR 102–3.150(b), 

less than 15 calendar days’ notice is 

being given for this meeting due to the 

exceptional circumstances of the 

COVID–19 pandemic and rapidly 


lotter on DSK11XQN23PROD with NOTICES1
38098 Federal Register / Vol. 86, No. 135 / Monday, July 19, 2021 / Notices 

evolving COVID–19 vaccine 

development and regulatory processes. 

The Secretary of Health and Human 

Services has determined that COVID–19 

is a Public Health Emergency. A notice 

of this ACIP meeting has also been 

posted on CDC’s ACIP website at: http:// 

www.cdc.gov/vaccines/acip/index.html. 

In addition, CDC has sent notice of this 

ACIP meeting by email to those who 

subscribe to receive email updates about 

ACIP. 

Purpose: The committee is charged 

with advising the Director, CDC, on the 

use of immunizing agents. In addition, 

under 42 U.S.C. 1396s, the committee is 

mandated to establish and periodically 

review and, as appropriate, revise the 

list of vaccines for administration to 

vaccine-eligible children through the 

Vaccines for Children (VFC) program, 

along with schedules regarding dosing 

interval, dosage, and contraindications 

to administration of vaccines. Further, 

under provisions of the Affordable Care 

Act, section 2713 of the Public Health 

Service Act, immunization 

recommendations of the ACIP that have 

been approved by the Director of the 

Centers for Disease Control and 

Prevention and appear on CDC 

immunization schedules must be 

covered by applicable health plans. 

Matters To Be Considered: The agenda 

will include discussions on COVID–19 

vaccine safety. Agenda items are subject 

to change as priorities dictate. For more 

information on the meeting agenda visit 

https://www.cdc.gov/vaccines/acip/ 

meetings/meetings-info.html. 

Meeting Information: The meeting 

will be webcast live via the World Wide 

Web; for more information on ACIP 

please visit the ACIP website: http://

www.cdc.gov/vaccines/acip/index.html. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials, are part of 

the public record and are subject to 

public disclosure. Comments will be 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

CDC will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near duplicate examples of a mass-mail 

campaign. CDC will carefully consider 

all comments submitted into the docket. 

Written Public Comment: Written 

comments must be received on or before 

July 22, 2021. 

Oral Public Comment: This meeting 

will include time for members of the 

public to make an oral comment. Oral 

public comment will occur before any 

scheduled votes including all votes 

relevant to the ACIP’s Affordable Care 

Act and Vaccines for Children Program 

roles. Priority will be given to 

individuals who submit a request to 

make an oral public comment before the 

meeting according to the procedures 

below. 

Procedure for Oral Public Comment: 

All persons interested in making an oral 

public comment at the July 22, 2021, 

ACIP meeting must submit a request at 

http://www.cdc.gov/vaccines/acip/ 

meetings/ no later than 11:59 p.m., EDT, 

July 20, 2021, according to the 

instructions provided. 

If the number of persons requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

time, CDC will conduct a lottery to 

determine the speakers for the 

scheduled public comment session. 

CDC staff will notify individuals 

regarding their request to speak by email 

by 12:00 p.m., EDT, July 21, 2021. To 

accommodate the significant interest in 

participation in the oral public 

comment session of ACIP meetings, 

each speaker will be limited to 3 

minutes, and each speaker may only 

speak once per meeting. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–15322 Filed 7–14–21; 4:15 pm] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–21–21GO; Docket No. CDC–2021– 

0068] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled Evaluating the use of EHMRs in 

health settings to improve 

organizational implementation and 

worker adoption during and after the 

COVID–19 pandemic. NIOSH proposes 

using surveys and interviews to 

understand how elastomeric half mask 

respirators (EHMRs) are being perceived 

and used by healthcare and first 

responder settings during the COVID–19 

pandemic. 

DATES: CDC must receive written 

comments on or before September 17, 

2021. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2021– 

0068 by any of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road, NE, MS–D74, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

Regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 


lotter on DSK11XQN23PROD with NOTICES1